|Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry).|
|PMID: 20542775 Owner: NLM Status: MEDLINE|
|AIMS: Limited data are available on the long-term outcome following PCI with paclitaxel-eluting stent (PES) implantation in patients with unprotected left main coronary artery (LMCA). The objective of this study was to evaluate "real world" long-term outcome following paclitaxel-eluting stent (PES) implantation for unprotected LMCA disease in patients enrolled in the TRUE registry.
METHODS AND RESULTS: From March 2003 to October 2004, 93 consecutive patients (81.7% male) underwent PCI for unprotected LMCA disease. Surveillance angiography was performed at 6.8+/-3.3 months follow-up. The target lesion involved the distal LMCA in 68 (73.1%) patients. Double stenting techniques were performed in 46 (67.6%) distal LMCA, of these 50% were stented using the Crush technique. Clinical follow-up was complete in all patients with 85.8% angiographic follow-up rate. In-segment restenosis occurred in 16 (20.3%) patients and was focal in 72.4% of cases and significantly higher in patients with distal LMCA (36.8% vs. 13.6%, p<0.04). At a median follow-up of 1,450 days (IQR 1281-1595), the overall incidence of MACE was 35.5% and the TLR rate was 25.8% and significantly higher in patients with bifurcation stenting (32.3% vs. 8%, p<0.02). The estimated cardiac survival rate at one and four years was 96.7% and 93.3%, respectively. Total mortality rate was 14.1% and cardiac was 6.5%. There was one (1.1%) definite stent thrombosis (ST) and one (1.1%) probable ST.
CONCLUSIONS: Treatment of unprotected LMCA disease with PES, after four years follow-up, appears to be safe and effective with a low rate of cardiac mortality and overall risk of ST. The need for target lesion revascularisation in 25.8% of patients highlights the need for more effective PCI especially in patients with distal LMCA disease.
|Cosmo Godino; Guido Parodi; Shinichi Furuichi; Azeem Latib; Rossella Barbagallo; Omer Goktekin; Michela Cera; Ralf Mueller; Corrado Tamburino; Eberhard Grube; Carlo Di Mario; Bernard Reimers; Alaide Chieffo; David Antoniucci; Antonio Colombo; Giuseppe M Sangiorgi|
Related Documents :
|25230745 - Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis.
23554855 - Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for sever...
21733455 - Star™ ankle: long-term results.
19717185 - Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction ...
3545965 - Failure of a cytoprotective dose of arbaprostil to heal acute duodenal ulcers. results ...
17765775 - Prospective, randomized, controlled trial of a hemostatic sealant in children undergoin...
|Type: Journal Article; Multicenter Study|
|Title: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology Volume: 5 ISSN: 1969-6213 ISO Abbreviation: EuroIntervention Publication Date: 2010 Apr|
|Created Date: 2010-06-14 Completed Date: 2010-09-27 Revised Date: 2011-02-22|
Medline Journal Info:
|Nlm Unique ID: 101251040 Medline TA: EuroIntervention Country: France|
|Languages: eng Pagination: 906-16 Citation Subset: IM|
|San Raffaele Institute, Milan, Italy. firstname.lastname@example.org <email@example.com>|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Angioplasty, Balloon, Coronary / adverse effects, instrumentation*, mortality
Cardiovascular Agents / administration & dosage*
Coronary Artery Disease / mortality, radiography, therapy*
Coronary Restenosis / etiology
Europe / epidemiology
Myocardial Infarction / etiology
Paclitaxel / administration & dosage*
Severity of Illness Index
Thrombosis / etiology
|0/Cardiovascular Agents; 33069-62-4/Paclitaxel|
|EuroIntervention. 2011 Feb;6(7):904-5
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis...
Next Document: Carotid artery revascularisation in high-surgical-risk patients with the NexStent and the FilterWire...